As chiral molecules, naturally occurring d‐oligonucleotides have enantiomers, l‐DNA and l‐RNA, which are comprised of l‐(deoxy)ribose sugars. These mirror‐image oligonucleotides have the same physical and chemical properties as that of their native d‐counterparts, yet are highly orthogonal to the stereospecific environment of biology. Consequently, l‐oligonucleotides are resistant to nuclease degradation and many of the off‐target interactions that plague traditional d‐oligonucleotide‐based technologies; thus making them ideal for biomedical applications. Despite a flurry of interest during the early 1990s, the inability of d‐ and l‐oligonucleotides to form contiguous Watson–Crick base pairs with each other has ultimately led to the perception that l‐oligonucleotides have only limited utility. Recently, however, scientists have begun to uncover novel strategies to harness the bio‐orthogonality of l‐oligonucleotides, while overcoming (and even exploiting) their inability to Watson–Crick base pair with the natural polymer. Herein, a brief history of l‐oligonucleotide research is presented and emerging l‐oligonucleotide‐based technologies, as well as their applications in research and therapy, are presented.